The group has secured two public procurement awards in molecular diagnostics for oncohematology within a few weeks, strengthening its presence in the public hospital channel.
The group has secured two public procurement awards in molecular diagnostics for oncohematology within a few weeks, strengthening its presence in the public hospital channel — one of the strategic priorities the management had outlined in the growth plan presented at the end of 2024.
The "Annunziata – Mariano Santo – S. Barbara" Hospital of Cosenza selected Helyx, throught its subsidiary Hyris S.r.l., to supply systems, reagents and consumables for oncohematology molecular diagnostics using the Real Time method, for the Clinical Chemistry and Analysis Laboratory. The supply has a one-year duration and is valued at € 106,230 excluding VAT (Management Decision n. 674, June 4, 2026).
This result comes just weeks after another award obtained in Veneto, in a different procurement process but on the same application area.
The ULSS n.1 Dolomiti Health Authority had already selected Helyx Industries, to supply a system for the molecular diagnostics of chronic myeloproliferative diseases — detection of mutations in the JAK2, CALR and MPL genes — for the Pathological Anatomy unit of Belluno Hospital. The system is based on the Hyris bCUBE 2.0 platform and the offer was deemed the most suitable both technically and economically. The contract is valued at € 109,800 excluding VAT and runs through May 2029 (Resolution n. 677, May 8, 2026).
Both supplies fall within the Vytro division — focused on PCR kits and IVD reagents for hospitals, laboratories and diagnostic centres, covering oncohematology, genetics and pharmacogenetics. In these areas, Vytro also works through its partnership with Biomol Laboratories — an Italian IVD molecular diagnostics company with whom the collaboration has been active since 2023 — a relationship that is becoming one of the distinctive elements of the group's offering to clinical institutions.
"We look at these awards with satisfaction, but above all with the awareness of how much we still have to build. Vytro is a division whose potential we are only beginning to express, and the public hospital channel is one of the areas where we want to grow with method and consistency. This is a beginning, and it commits us to do more."
Gabriele Salaris, Head of Marketing & Sales, Helyx Industries
